3.99 USD
-0.07 (-1.72%)
3.99 USD
0 (0%)
Taking everything into account, CLLS scores 2 out of 10 in our fundamental rating. CLLS was compared to 525 industry peers in the Biotechnology industry. CLLS may be in some trouble as it scores bad on both profitability and health. CLLS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- CLLS had negative earnings in the past year.
- In the past year CLLS has reported a negative cash flow from operations.
- CLLS had negative earnings in each of the past 5 years.
- CLLS had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- CLLS's Return On Assets of -28.25% is fine compared to the rest of the industry. CLLS outperforms 68.57% of its industry peers.
- CLLS has a Return On Equity of -102.97%. This is comparable to the rest of the industry: CLLS outperforms 45.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.25% | ||
| ROE | -102.97% | ||
| ROIC | N/A |
ROA(3y)-26.82%
ROA(5y)-25.52%
ROE(3y)-79.12%
ROE(5y)-63.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CLLS has a better Gross Margin (3.66%) than 71.81% of its industry peers.
- The Profit Margin and Operating Margin are not available for CLLS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 3.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- CLLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for CLLS has been increased compared to 1 year ago.
- The number of shares outstanding for CLLS has been increased compared to 5 years ago.
- Compared to 1 year ago, CLLS has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -0.44, we must say that CLLS is in the distress zone and has some risk of bankruptcy.
- CLLS has a Altman-Z score (-0.44) which is comparable to the rest of the industry.
- CLLS has a Debt/Equity ratio of 0.91. This is a neutral value indicating CLLS is somewhat dependend on debt financing.
- CLLS has a worse Debt to Equity ratio (0.91) than 74.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.91 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.44 |
ROIC/WACCN/A
WACC6.73%
2.3 Liquidity
- A Current Ratio of 1.38 indicates that CLLS should not have too much problems paying its short term obligations.
- CLLS has a worse Current ratio (1.38) than 81.90% of its industry peers.
- A Quick Ratio of 1.38 indicates that CLLS should not have too much problems paying its short term obligations.
- CLLS's Quick ratio of 1.38 is on the low side compared to the rest of the industry. CLLS is outperformed by 80.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.38 |
3. Growth
3.1 Past
- CLLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.80%, which is quite impressive.
- The Revenue has grown by 154.92% in the past year. This is a very strong growth!
- Measured over the past years, CLLS shows a quite strong growth in Revenue. The Revenue has been growing by 16.44% on average per year.
EPS 1Y (TTM)70.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%104.35%
Revenue 1Y (TTM)154.92%
Revenue growth 3Y8.44%
Revenue growth 5Y16.44%
Sales Q2Q%105.89%
3.2 Future
- CLLS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -54.16% yearly.
- CLLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.15% yearly.
EPS Next Y-166.15%
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%
EPS Next 5YN/A
Revenue Next Year45.52%
Revenue Next 2Y32.52%
Revenue Next 3Y9.94%
Revenue Next 5Y25.15%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- CLLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLLS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- CLLS's earnings are expected to decrease with -54.16% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-83.7%
EPS Next 3Y-54.16%
5. Dividend
5.1 Amount
- No dividends for CLLS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CELLECTIS - ADR / CLLS FAQ
What is the ChartMill fundamental rating of CELLECTIS - ADR (CLLS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to CLLS.
Can you provide the valuation status for CELLECTIS - ADR?
ChartMill assigns a valuation rating of 0 / 10 to CELLECTIS - ADR (CLLS). This can be considered as Overvalued.
How profitable is CELLECTIS - ADR (CLLS) stock?
CELLECTIS - ADR (CLLS) has a profitability rating of 1 / 10.
What is the earnings growth outlook for CELLECTIS - ADR?
The Earnings per Share (EPS) of CELLECTIS - ADR (CLLS) is expected to decline by -166.15% in the next year.